"Exon" as an agent of rehabilitation for patients with viral infections - a brief review


  • Artur Martynov Mechnikov Institute of microbiology and immunology, Ukraine
  • Timur Lukianenko Kharkiv Regional Clinical Hospital, Ukraine




Exon is a composition of acidic peptides capable of self-organization and self-adaptation in the body, the mechanism of which is based on the blockade the nuclear import/export peptides and prevent crossing the nuclear membrane with virion fragments. The Exon selectively binds to importin’s signal peptides through molecular recognition and prevents the nuclear pore recognizing and opening for viral components. In fact, 90% of all viruses use the cell nucleus for increase the speed of their own replication. Adaptation to the drug is impossible on part of the virus and the human body due to the fact that it is a quasi-living system capable of self-organization and its composite pharmacophore adapts itself for each person and virus. The minimum effective concentration (MEC) of Exon against the influenza virus, which completely inhibits the synthesis of the virus, is 0.05 mg/mL. Effectiveness of Exon has a dose-dependent character. Also, Exon has a direct antiviral effect against the influenza virus (H3N2 and H1N1 srrains) and coronavirus. Exon also has a virustatic (inhibiting) and virulicidal (inactivating) effect on TGS and bovine diarrhea viruses. On basis of Exon it is possible to create chemical preparations for the treatment and prevention of infectious diseases of viral etiology in human. The chemotherapeutic index for rabbits with keratoconjunctivitis/encephalitis caused by HSV1 when using Exon was 1000, which indicates the promise of Exon as a highly effective antiviral substance with a broad action spectrum and low toxicity in the complex of rehabilitation measures for herpetic lesions. According to the results of the Exon use in the complex rehabilitation of patients with COVID-19, the patients recovery time is statistically significantly reduced according to two criteria: the time of disappearance of the viral antigen/RNA and the time of  Rx - normalization in the presence of pneumonia.


Jain S, Batra H, Yadav P, Chand S. Covid-19 vaccines currently under preclinical and clinical studies, and associated antiviral immune response. Vaccines. 2020. 8(4). 1-16. doi:10.3390/vaccines8040649

Martynov AV, Babkina MM, Zheynova NM. Antiviral activity of albuvir in models of vesicular stomatitis virus and human herpes virus type 1 in vitro. Scientific Bulletin of the Lviv National University of Veterinary Medicine and Biotechnology named after Gzhytsky. 2011.13. 2(1). 181-184.

Merchel Piovesan Pereira B, Tagkopoulos I. Benzalkonium chlorides: uses, regulatory status, and microbial resistance. Appl Environ Microbiol. 2019. 85(13). e00377-19.

Nosalskaya T, Martynov A, Bomko T. Ivermectin-molecular mechanisms of antivirus and antiparasitic effects. Ann Mechnikovs Inst. 2021.1.15-24.

Martynov AV, Smelyanskaya MV, Peremot SD. New approach to design and synthesis of therapeutic and preventive drugs, taking into account interspecies polymorphism of receptors (method of precision partial modification). Ann Mechnikovs Inst. 2007. 4. С. 5-15.

Farber B, Martynov A, Kleyn I. Creation of new medical drugs based on TRIZ and computer mathematical modeling. Ann Mechnikovs Inst. 2018. 4. 15-34.

Cai M, Chen D, Zeng Z, et al. Characterization of the nuclear import signal of herpes simplex virus 1 UL31. Arch Virol. 2016. 161(9). 2379-2385. doi:10.1007/s00705-016-2910-z

Tessier TM, Dodge MJ, Prusinkiewicz MA, Mymryk JS. Viral Appropriation: Laying Claim to Host Nuclear Transport Machinery. Cells. 2019. 8(6). 559. doi:10.3390/cells8060559

Lange A, Mills RE, Lange CJ, Stewart M, Devine SE, Corbett AH. Classical nuclear localization signals: Definition, function, and interaction with importin α. J Biol Chem. 2007. 282(8). 5101-5105. doi:10.1074/jbc.R600026200

Gussow AB, Auslander N, Faure G, Wolf YI, Zhang F, Koonin EV. Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. Proc Natl Acad Sci U S A. 2020. 117(26). 15193-15199. doi:10.1073/pnas.2008176117

Martynov A, Farber B, Farber S. Quasi-life self-organizing systems: based on ensembles of succinylated derivatives of interferon-gamma. Curr Med Chem. 2011. 18(22). 3431-3436.

Martynov AV, Bomko TV, Nosalskaya TN, Farber BS, Farber SB. Oral long-acting pharmaceutical form of insulin on the basis of self-organizing kvasi-living system of combinatorial peptides. Ann Mechnikovs Inst. 2012. 2. 64-70.

Farber B. Combinatorial derivatives of oligopeptides having antiviral properties. US Patent 11339502, 2022:15.

Farber B, Martynov A, Kleyn I. Reproduction and apoptosis of EBV-latent infected cells under influence a TRIZ-created antiviral drugs. Ann Mechnikovs Inst. 2020. 3. 58-67.

Organization WH. Home Care for Patients with Suspected or Confirmed COVID-19 and Management of Their Contacts. Interim Guidance. 2020. 2021.



How to Cite

Martynov, A., & Lukianenko, T. (2022). "Exon" as an agent of rehabilitation for patients with viral infections - a brief review. Annals of Mechnikov’s Institute, (3), 13–20. https://doi.org/10.5281/zenodo.7070875